Lilly's Donanemab Lowers Alzheimer's-Associated Biomarkers In Patients With Early Disease

  • Eli Lilly And Co LLY rolled out the new exploratory analyses of the Trailblazer Phase 2 trial at the Alzheimer's Association International Conference. 
  • According to a statement, the first analysis found that patients who received donanemab showed a more significant change in amyloid plaque levels, which was "highly associated with less cognitive decline," according to a statement. In that analysis, Lilly also found that participants who had greater plaque clearance at 24 weeks showed less tau progression.
  • The second analysis revealed that donanemab rapidly reduces another Alzheimer's related biomarker, called plasma P-tau217.
  • In the first analysis, patients with early symptomatic disease but with the most severe plaque burden showed the most rapid clearance. 
  • These patients were able to stop or reduce their dose of donanemab earlier than other patients.
  • Patients who had early complete clearance of plaques at 24 weeks showed a decrease in the spread of tau in imaging scans done at 76 weeks compared to placebo, a predictive biomarker for Alzheimer's.
  • Earlier results from the phase 2 study issued in March showed that donanemab met its goal of improving cognitive dysfunction in patients with low-to-medium presence of tau.
  • Price Action: LLY shares closed at $245.33 on Thursday.

Posted In: Alzheimer's diseaseBriefsBiotechNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.